Xencor reported $879.42M in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
Arrowhead Research USD 1.38B 192.89M Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Cytokinetics USD 1.23B 38.42M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
J&J USD 193.67B 13.57B Mar/2025
MacroGenics USD 245.42M 16.24M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Xencor USD 879.42M 25.26M Jun/2025